Phase 2 N=8 CYstic Fibrosis bacterioPHage Study at Yale (CYPHY)
Cystic Fibrosis
Primary: Change in Sputum Bacterial Culture — -0.59; -0.89 CFU/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=4 Radiation and Combination Immunotherapy for Melanoma
Metastatic Melanoma
Primary: Objective Response Rate (ORR) — 1; 1 Participants
Phase 2 N=41 Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma
AIDS-Related Hodgkin Lymphoma · Ann Arbor Stage II Hodgkin Lymphoma · Ann Arbor Stage IIA Hodgkin Lymphoma
Primary: Maximal Tolerated Dose of Brentuximab Vedotin (Phase I) — 1.2 mg/kg
Phase 3 N=745 Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection
Clostridioides Difficile Infection
Primary: Number of Participants With Sustained Clinical Response (SCR) Defined as Clinical Response and no Recurrence of CDI Through 30 Days Post End of Treatment (EOT). — 238…
Phase 1 N=12 Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Recurrent Acute Myeloid Leukemia · Recurrent Myelodysplastic Syndrome
Primary: Number of Participants With Dose Limiting Toxicities of MLN4924 (Pevonedistat) — 1; 2 Participants
Phase 1 N=37 Safety and Pharmacokinetics of Two Vaginal Film Formulations Containing the Integrase Inhibitor MK-2048
Pharmacokinetics · Safety
Primary: Number of Participants With Grade 2 or Higher Adverse Events — 2; 5 Participants — p=.025
Phase 4 N=26 Efficacy and Tolerability of Combination Varenicline With Hydroxyzine as a Potential Smoking Cessation Treatment
Smoking Cessation · Stress · Sleep Disturbance
Primary: Change in 10-item Perceived Stress Scale (PSS-10) Following Smoking Cessation (While Taking Arenicline and Hydroxyzine). — -1.38; -1.48; -1.55; -2.05 score on a scale
N/A N=450 Using Peer Support to Aid in Prevention and Treatment in Prediabetes
PreDiabetes
Primary: Change in Glycosylated Hemoglobin A1c (HbA1c) at 6 Months — -0.07; -0.06 Percentage — p=0.7436
Phase 2 N=50 A Multiple Ascending Dose Study of HTD1801 in Adults With Hypercholesterolemia
Hypercholesterolemia
Primary: Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) — 8; 10; 8; 11 Participants
Phase 3 N=146 Peanut Oral Immunotherapy Study of Early Intervention for Desensitization
Peanut Allergy
Primary: Percentage of Subjects Who Tolerated a Single Highest Dose of at Least 600 mg in the Exit Double-Blind, Placebo-Controlled Food Challenge (DBPCFC) — 73.5; 6.3 Percentage…
N/A N=60 Congenital Heart Disease Physical Activity Lifestyle Study
Cardiovascular Disease Other · Physical Activity
Primary: Moderate to Vigorous Physical Activity (MVPA) — -1.9; 3.4 average minutes per day — p=0.24
Phase 4 N=67 Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes
Type 2 Diabetes Mellitus · Insomnia · Sleep Disorder
Primary: Subjective Total Sleep Time — 6.4; 7.0; 6.7; 6.7 hours — p=0.15
Phase 4 N=248 Antibiotic Resistance and Microbiome in Children Aged 6-59 Months in Nouna, Burkina Faso
Child Development
Primary: Simpson's Index of Diversity (Alpha Diversity) in Intestinal Microbiome — 10.2; 8.8; 9.7; 9.6 Index score
Phase 2 N=162 Acetaminophen Versus IV Hydromorphone for Pain in the Elderly in the ED
Acute Pain
Primary: Clinical Improvement in NRS Pain Score — 62; 63 Participants
Phase 2 N=26 Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma
Stage IV Melanoma · Stage III Melanoma · Advanced Melanoma
Primary: Maximally Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) of Pembrolizumab — 200 mg